Toronto Dominion Bank lifted its stake in Edwards Lifesciences Corp (NYSE:EW) by 19.5% in the second quarter, HoldingsChannel.com reports. The firm owned 135,424 shares of the medical research company’s stock after purchasing an additional 22,101 shares during the period. Toronto Dominion Bank’s holdings in Edwards Lifesciences were worth $19,709,000 at the end of the most recent quarter.
Several other large investors also recently added to or reduced their stakes in EW. Optimum Investment Advisors acquired a new stake in Edwards Lifesciences during the 1st quarter worth about $110,000. IHT Wealth Management LLC boosted its position in Edwards Lifesciences by 84.6% during the 1st quarter. IHT Wealth Management LLC now owns 932 shares of the medical research company’s stock worth $126,000 after acquiring an additional 427 shares during the period. Well Done LLC acquired a new stake in Edwards Lifesciences during the 1st quarter worth about $152,000. Fagan Associates Inc. acquired a new stake in Edwards Lifesciences during the 2nd quarter worth about $201,000. Finally, Peregrine Asset Advisers Inc. acquired a new stake in Edwards Lifesciences during the 1st quarter worth about $204,000. Institutional investors and hedge funds own 81.53% of the company’s stock.
Shares of EW stock opened at $139.77 on Friday. The company has a current ratio of 1.86, a quick ratio of 1.47 and a debt-to-equity ratio of 0.19. Edwards Lifesciences Corp has a twelve month low of $100.20 and a twelve month high of $156.87. The company has a market capitalization of $28.91 billion, a P/E ratio of 36.78, a P/E/G ratio of 2.01 and a beta of 0.60.
Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, July 26th. The medical research company reported $1.24 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.13 by $0.11. Edwards Lifesciences had a return on equity of 29.11% and a net margin of 19.59%. The business had revenue of $972.00 million for the quarter, compared to the consensus estimate of $968.32 million. During the same period last year, the business earned $1.08 EPS. The firm’s revenue was up 10.0% compared to the same quarter last year. research analysts forecast that Edwards Lifesciences Corp will post 4.66 EPS for the current year.
Several equities research analysts have recently issued reports on the company. Zacks Investment Research lowered Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Monday, July 16th. Citigroup lifted their price target on Edwards Lifesciences from $115.00 to $118.00 and gave the company a “sell” rating in a report on Tuesday, July 31st. ValuEngine upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Monday, May 7th. SunTrust Banks reduced their price target on Edwards Lifesciences to $170.00 and set a “buy” rating for the company in a report on Friday, August 10th. Finally, Raymond James assumed coverage on Edwards Lifesciences in a report on Thursday, May 31st. They set an “outperform” rating and a $152.00 price target for the company. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and fifteen have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $152.45.
In other Edwards Lifesciences news, CFO Scott B. Ullem sold 25,000 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, June 6th. The stock was sold at an average price of $141.07, for a total value of $3,526,750.00. Following the transaction, the chief financial officer now directly owns 41,265 shares of the company’s stock, valued at approximately $5,821,253.55. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Michael A. Mussallem sold 32,900 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, July 31st. The stock was sold at an average price of $141.86, for a total value of $4,667,194.00. Following the completion of the transaction, the chief executive officer now directly owns 43,126 shares in the company, valued at $6,117,854.36. The disclosure for this sale can be found here. Insiders sold a total of 160,615 shares of company stock worth $23,053,493 over the last three months. 1.84% of the stock is owned by company insiders.
Edwards Lifesciences Profile
Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.